PL1673473T3 - Zastosowanie polimorfizmów genetycznych związanych ze skutecznością leczenia chorób zapalnych - Google Patents
Zastosowanie polimorfizmów genetycznych związanych ze skutecznością leczenia chorób zapalnychInfo
- Publication number
- PL1673473T3 PL1673473T3 PL04765831T PL04765831T PL1673473T3 PL 1673473 T3 PL1673473 T3 PL 1673473T3 PL 04765831 T PL04765831 T PL 04765831T PL 04765831 T PL04765831 T PL 04765831T PL 1673473 T3 PL1673473 T3 PL 1673473T3
- Authority
- PL
- Poland
- Prior art keywords
- treatment
- efficacy
- inflammatory disease
- genetic polymorphisms
- associate
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pathology (AREA)
- Rheumatology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Dermatology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US50897103P | 2003-10-06 | 2003-10-06 | |
EP04765831A EP1673473B1 (en) | 2003-10-06 | 2004-10-05 | Use of genetic polymorphisms that associate with efficacy of treatment of inflammatory disease |
PCT/EP2004/011124 WO2005040416A1 (en) | 2003-10-06 | 2004-10-05 | Use of genetic polymorphisms that associate with efficacy of treatment of inflammatory disease |
Publications (1)
Publication Number | Publication Date |
---|---|
PL1673473T3 true PL1673473T3 (pl) | 2011-12-30 |
Family
ID=34520002
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL04765831T PL1673473T3 (pl) | 2003-10-06 | 2004-10-05 | Zastosowanie polimorfizmów genetycznych związanych ze skutecznością leczenia chorób zapalnych |
Country Status (13)
Country | Link |
---|---|
US (1) | US20070155772A1 (pl) |
EP (1) | EP1673473B1 (pl) |
JP (1) | JP2007507460A (pl) |
CN (1) | CN1890384A (pl) |
AT (1) | ATE515577T1 (pl) |
AU (1) | AU2004283235B2 (pl) |
BR (1) | BRPI0415302A (pl) |
CA (1) | CA2541138A1 (pl) |
ES (1) | ES2367566T3 (pl) |
MX (1) | MXPA06003828A (pl) |
PL (1) | PL1673473T3 (pl) |
PT (1) | PT1673473E (pl) |
WO (1) | WO2005040416A1 (pl) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1610823B1 (en) | 2003-03-28 | 2011-09-28 | Innovational Holdings, LLC | Implantable medical device with continuous agent concentration gradient |
WO2012019168A2 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
DE19177059T1 (de) | 2010-10-01 | 2021-10-07 | Modernatx, Inc. | N1-methyl-pseudouracile enthältendes ribonucleinsäuren sowie ihre verwendungen |
WO2012116081A2 (en) | 2011-02-22 | 2012-08-30 | The Procter & Gamble Company | Methods for identifying cosmetic agents for skin care compositions |
CA2831613A1 (en) | 2011-03-31 | 2012-10-04 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
JP5841234B2 (ja) | 2011-03-31 | 2016-01-13 | ザ プロクター アンド ギャンブルカンパニー | フケ/脂漏性皮膚炎の治療に有効な皮膚活性剤を特定及び評価するためのシステム、モデル、及び方法 |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
EP2763701B1 (en) | 2011-10-03 | 2018-12-19 | Moderna Therapeutics, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
AU2012352180A1 (en) | 2011-12-16 | 2014-07-31 | Moderna Therapeutics, Inc. | Modified nucleoside, nucleotide, and nucleic acid compositions |
JP2015519880A (ja) | 2012-03-30 | 2015-07-16 | ザ プロクター アンド ギャンブルカンパニー | 摂動因子及び皮膚の色素沈着過剰状態に関連する遺伝子間の関連性を特定するためのシステム |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
WO2013151663A1 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of membrane proteins |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9254311B2 (en) | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
WO2013184908A2 (en) | 2012-06-06 | 2013-12-12 | The Procter & Gamble Company | Systems and methods for identifying cosmetic agents for hair/scalp care compositions |
EP2885423B1 (en) * | 2012-08-15 | 2017-09-27 | The Procter and Gamble Company | Systems for identifying and evaluating skin-active agents effective for treating an array of skin disorders |
RS63237B1 (sr) | 2012-11-26 | 2022-06-30 | Modernatx Inc | Terminalno modifikovana rnk |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
BR112016007255A2 (pt) | 2013-10-03 | 2017-09-12 | Moderna Therapeutics Inc | polinucleotídeos que codificam receptor de lipoproteína de baixa densidade |
ES2548793B1 (es) * | 2014-03-17 | 2016-07-07 | Fundacion Para La Investigacion Biomedica Del Hospital Universitario La Princesa | Método pronóstico de enfermedades autoinmunes mediante el genotipado de variantes genéticas del péptido intestinal vasoactivo |
US11946927B2 (en) | 2016-03-14 | 2024-04-02 | Musidora Biotechnology Llc | Process and system for identifying individuals having a high risk of inflammatory bowel disease and a method of treatment |
US10295527B2 (en) | 2016-03-14 | 2019-05-21 | Bruce Yacyshyn | Process and system for predicting responders and non-responders to mesalamine treatment of ulcerative colitis |
CN109476698B (zh) * | 2016-05-20 | 2023-10-17 | 西达-赛奈医疗中心 | 基于基因的炎性肠病诊断 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3888224T2 (de) * | 1987-04-24 | 1994-07-21 | Teijin Ltd | Bestimmung vom Tumornekrosefaktor; monoklonaler Antikörper und Zusammensetzung. |
US6235723B1 (en) * | 1992-03-16 | 2001-05-22 | Isis Pharmaceuticals , Inc. | Antisense oligonucleotide modulation of human protein kinase C-δ expression |
BR0209474A (pt) * | 2001-05-09 | 2006-02-07 | Novartis Ag | Métodos para imunomodulação seletiva |
-
2004
- 2004-10-05 BR BRPI0415302-2A patent/BRPI0415302A/pt not_active IP Right Cessation
- 2004-10-05 MX MXPA06003828A patent/MXPA06003828A/es not_active Application Discontinuation
- 2004-10-05 PL PL04765831T patent/PL1673473T3/pl unknown
- 2004-10-05 AT AT04765831T patent/ATE515577T1/de active
- 2004-10-05 US US10/574,770 patent/US20070155772A1/en not_active Abandoned
- 2004-10-05 CN CNA2004800358001A patent/CN1890384A/zh active Pending
- 2004-10-05 CA CA002541138A patent/CA2541138A1/en not_active Abandoned
- 2004-10-05 AU AU2004283235A patent/AU2004283235B2/en not_active Ceased
- 2004-10-05 JP JP2006530098A patent/JP2007507460A/ja active Pending
- 2004-10-05 WO PCT/EP2004/011124 patent/WO2005040416A1/en active IP Right Grant
- 2004-10-05 EP EP04765831A patent/EP1673473B1/en not_active Expired - Lifetime
- 2004-10-05 ES ES04765831T patent/ES2367566T3/es not_active Expired - Lifetime
- 2004-10-05 PT PT04765831T patent/PT1673473E/pt unknown
Also Published As
Publication number | Publication date |
---|---|
PT1673473E (pt) | 2011-09-19 |
MXPA06003828A (es) | 2006-06-14 |
BRPI0415302A (pt) | 2006-12-05 |
ATE515577T1 (de) | 2011-07-15 |
AU2004283235B2 (en) | 2007-08-02 |
US20070155772A1 (en) | 2007-07-05 |
AU2004283235A1 (en) | 2005-05-06 |
ES2367566T3 (es) | 2011-11-04 |
WO2005040416A1 (en) | 2005-05-06 |
EP1673473A1 (en) | 2006-06-28 |
CN1890384A (zh) | 2007-01-03 |
CA2541138A1 (en) | 2005-05-06 |
JP2007507460A (ja) | 2007-03-29 |
EP1673473B1 (en) | 2011-07-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PT1673473E (pt) | Utilização de polimorfismos genéticos associados à eficácia do tratamento de doenças inflamatórias | |
EP2631293A3 (en) | Human microRNAs and methods for inhibiting same | |
EP2514826A3 (en) | Use of interfering RNA molecules to down regulate the expression of specific genes or family of genes | |
EP2423326A3 (en) | Genetic polymorphisms associated with liver fibrosis methods of detection and uses thereof | |
WO2001090419A3 (en) | Methods for genetic analysis of dna to detect sequence variances | |
WO2004035803A3 (en) | Method and nucleic acids for the treatment of breast cell proliferative disorders | |
EP2639318A3 (en) | Genetic polymorphisms associated with Psoriasis, methods of detection and uses thereof | |
ATE394674T1 (de) | Funktionalisierte nanopartikel und verwendungsverfahren | |
WO2007085497A8 (en) | Markers for the prediction of outcome of anthracycline treatment | |
WO2006138606A3 (en) | Cell signaling genes and related methods | |
WO2008008553A3 (en) | Genetic polymorphisms associated with alzheimer's disease, methods of detection and uses thereof | |
WO2005087953A3 (en) | Genetic polymorphisms associated with coronary heart disease, methods of detection and uses thereof | |
PL1730315T3 (pl) | Polimorfizmy w genie NOD2/CARD15 | |
ATE513929T1 (de) | Gene mit einfluss auf die menschliche gedächtnisleistung | |
WO2005112544A3 (en) | Leptin promoter polymorphisms and uses thereof | |
WO2007124157A3 (en) | Genetic polymorphisms associated with coronary heart disease, methods of detection and uses thereof | |
WO2006133866A3 (en) | Prognostic markers for prediction of treatment response and/or survival of breast cell proliferative disorder patients | |
WO2009046422A3 (en) | Polymorphic nucleic acids associated with colorectal cancer and uses thereof | |
MD3300G2 (ro) | Primer oligonucleotidic pentru depistarea ARN-ului virusului hepatitei C | |
MX2013013023A (es) | Analisis y metodo para la identificacion de la capacidad de respuestas individual a tratamiento con inmunoglobulina. | |
GB2489180A (en) | Method of predicting capecitabine toxicity | |
EP1531184A3 (en) | Kit and method for genetic testing of bladder cancer | |
EP1870470A3 (en) | Method and kit for expressing protein under regulation of the expression from repeated sequence formed by gene amplification and transformant | |
WO2008073746A3 (en) | Expression of toxic genes in vivo in a non-natural host | |
NZ588905A (en) | Genetic testing method for determining susceptibility to abdominal aortic aneurysm by assay for selected polymorphisms associated with the disease |